APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

IL-23 Receptor Antagonist

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global IL-23 Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174001630327 December 2025199 pages

Choose your research edition.

Industry ResearchIL-23 Receptor Antagonist Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-23 Receptor Antagonist Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal IL-23 Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-23 Receptor Antagonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-23 Receptor Antagonist Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global IL-23 Receptor Antagonist market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for IL-23 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IL-23 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IL-23 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for IL-23 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of IL-23 Receptor Antagonist include Qyuns Therapeutics, China Medical System, Huadong Medicine, Bio-Thera Solutions, Teva, Sun Pharma, Sandoz, Samsung Bioepis and Janssen Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IL-23 Receptor Antagonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IL-23 Receptor Antagonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IL-23 Receptor Antagonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IL-23 Receptor Antagonist market size, projected growth trends, production technologies, key applications, and end-use industries.

IL-23 Receptor Antagonist Segment by Company

Qyuns Therapeutics

China Medical System

Huadong Medicine

Bio-Thera Solutions

Teva

Sun Pharma

Sandoz

Samsung Bioepis

Janssen Pharmaceuticals

Eli Lilly

Celltrion

Biocon Biologics

Amgen

Almirall

AbbVie Biotechnology

IL-23 Receptor Antagonist Segment by Type

Briakinumab

Guselkumab

Mirikizumab

Risankizumab

Tildrakizumab

Ustekinumab

Other

IL-23 Receptor Antagonist Segment by Application

Plaque Psoriasis

Crohn's Disease

Psoriatic Arthritis

Other

IL-23 Receptor Antagonist Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-23 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-23 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-23 Receptor Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IL-23 Receptor Antagonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of IL-23 Receptor Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of IL-23 Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of IL-23 Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. IL-23 Receptor Antagonist Industry Trends Table 2. IL-23 Receptor Antagonist Industry Drivers Table 3. IL-23 Receptor Antagonist Industry Opportunities and Challenges Table 4. IL-23 Receptor Antagonist Industry Restraints Table 5. Global IL-23 Receptor Antagonist Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global IL-23 Receptor Antagonist Revenue Market Share by Manufacturers (2021-2026) Table 7. Global IL-23 Receptor Antagonist Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global IL-23 Receptor Antagonist Sales Market Share by Manufacturers Table 9. Global IL-23 Receptor Antagonist Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global IL-23 Receptor Antagonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global IL-23 Receptor Antagonist Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global IL-23 Receptor Antagonist Manufacturers, Product Type & Application Table 13. Global IL-23 Receptor Antagonist Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global IL-23 Receptor Antagonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Briakinumab Table 17. Major Manufacturers of Guselkumab Table 18. Major Manufacturers of Mirikizumab Table 19. Major Manufacturers of Risankizumab Table 20. Major Manufacturers of Tildrakizumab Table 21. Major Manufacturers of Ustekinumab Table 22. Major Manufacturers of Other Table 23. Global IL-23 Receptor Antagonist Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global IL-23 Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 25. Global IL-23 Receptor Antagonist Sales by Type (2027-2032) & (K Units) Table 26. Global IL-23 Receptor Antagonist Sales Market Share by Type (2021-2026) Table 27. Global IL-23 Receptor Antagonist Sales Market Share by Type (2027-2032) Table 28. Global IL-23 Receptor Antagonist Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 29. Global IL-23 Receptor Antagonist Revenue by Type (2021-2026) & (K Units) Table 30. Global IL-23 Receptor Antagonist Revenue by Type (2027-2032) & (K Units) Table 31. Global IL-23 Receptor Antagonist Revenue Market Share by Type (2021-2026) Table 32. Global IL-23 Receptor Antagonist Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Plaque Psoriasis Table 34. Major Manufacturers of Crohn's Disease Table 35. Major Manufacturers of Psoriatic Arthritis Table 36. Major Manufacturers of Other Table 37. Global IL-23 Receptor Antagonist Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global IL-23 Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 39. Global IL-23 Receptor Antagonist Sales by Application (2027-2032) & (K Units) Table 40. Global IL-23 Receptor Antagonist Sales Market Share by Application (2021-2026) Table 41. Global IL-23 Receptor Antagonist Sales Market Share by Application (2027-2032) Table 42. Global IL-23 Receptor Antagonist Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 43. Global IL-23 Receptor Antagonist Revenue by Application (2021-2026) & (K Units) Table 44. Global IL-23 Receptor Antagonist Revenue by Application (2027-2032) & (K Units) Table 45. Global IL-23 Receptor Antagonist Revenue Market Share by Application (2021-2026) Table 46. Global IL-23 Receptor Antagonist Revenue Market Share by Application (2027-2032) Table 47. Global IL-23 Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global IL-23 Receptor Antagonist Sales by Region (2021-2026) & (K Units) Table 49. Global IL-23 Receptor Antagonist Sales Market Share by Region (2021-2026) Table 50. Global IL-23 Receptor Antagonist Sales Forecasted by Region (2027-2032) & (K Units) Table 51. Global IL-23 Receptor Antagonist Sales Forecasted Market Share by Region (2027-2032) Table 52. North America IL-23 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. North America IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 54. North America IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 55. Europe IL-23 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Europe IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 57. Europe IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 58. Asia Pacific IL-23 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Asia Pacific IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 60. Asia Pacific IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 61. South America, Middle East and Africa IL-23 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 62. South America, Middle East and Africa IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 63. South America, Middle East and Africa IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 64. Global IL-23 Receptor Antagonist Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global IL-23 Receptor Antagonist Revenue by Region (2021-2026) & (US$ Million) Table 66. Global IL-23 Receptor Antagonist Revenue by Region (2027-2032) & (US$ Million) Table 67. Global IL-23 Receptor Antagonist Revenue Market Share by Region (2021-2026) Table 68. Global IL-23 Receptor Antagonist Revenue Market Share by Region (2027-2032) Table 69. Qyuns Therapeutics Company Information Table 70. Qyuns Therapeutics Business Overview Table 71. Qyuns Therapeutics IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Qyuns Therapeutics IL-23 Receptor Antagonist Product Portfolio Table 73. Qyuns Therapeutics Recent Development Table 74. China Medical System Company Information Table 75. China Medical System Business Overview Table 76. China Medical System IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. China Medical System IL-23 Receptor Antagonist Product Portfolio Table 78. China Medical System Recent Development Table 79. Huadong Medicine Company Information Table 80. Huadong Medicine Business Overview Table 81. Huadong Medicine IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Huadong Medicine IL-23 Receptor Antagonist Product Portfolio Table 83. Huadong Medicine Recent Development Table 84. Bio-Thera Solutions Company Information Table 85. Bio-Thera Solutions Business Overview Table 86. Bio-Thera Solutions IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Bio-Thera Solutions IL-23 Receptor Antagonist Product Portfolio Table 88. Bio-Thera Solutions Recent Development Table 89. Teva Company Information Table 90. Teva Business Overview Table 91. Teva IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Teva IL-23 Receptor Antagonist Product Portfolio Table 93. Teva Recent Development Table 94. Sun Pharma Company Information Table 95. Sun Pharma Business Overview Table 96. Sun Pharma IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Sun Pharma IL-23 Receptor Antagonist Product Portfolio Table 98. Sun Pharma Recent Development Table 99. Sandoz Company Information Table 100. Sandoz Business Overview Table 101. Sandoz IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Sandoz IL-23 Receptor Antagonist Product Portfolio Table 103. Sandoz Recent Development Table 104. Samsung Bioepis Company Information Table 105. Samsung Bioepis Business Overview Table 106. Samsung Bioepis IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Samsung Bioepis IL-23 Receptor Antagonist Product Portfolio Table 108. Samsung Bioepis Recent Development Table 109. Janssen Pharmaceuticals Company Information Table 110. Janssen Pharmaceuticals Business Overview Table 111. Janssen Pharmaceuticals IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Janssen Pharmaceuticals IL-23 Receptor Antagonist Product Portfolio Table 113. Janssen Pharmaceuticals Recent Development Table 114. Eli Lilly Company Information Table 115. Eli Lilly Business Overview Table 116. Eli Lilly IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Eli Lilly IL-23 Receptor Antagonist Product Portfolio Table 118. Eli Lilly Recent Development Table 119. Celltrion Company Information Table 120. Celltrion Business Overview Table 121. Celltrion IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Celltrion IL-23 Receptor Antagonist Product Portfolio Table 123. Celltrion Recent Development Table 124. Biocon Biologics Company Information Table 125. Biocon Biologics Business Overview Table 126. Biocon Biologics IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Biocon Biologics IL-23 Receptor Antagonist Product Portfolio Table 128. Biocon Biologics Recent Development Table 129. Amgen Company Information Table 130. Amgen Business Overview Table 131. Amgen IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Amgen IL-23 Receptor Antagonist Product Portfolio Table 133. Amgen Recent Development Table 134. Almirall Company Information Table 135. Almirall Business Overview Table 136. Almirall IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Almirall IL-23 Receptor Antagonist Product Portfolio Table 138. Almirall Recent Development Table 139. AbbVie Biotechnology Company Information Table 140. AbbVie Biotechnology Business Overview Table 141. AbbVie Biotechnology IL-23 Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. AbbVie Biotechnology IL-23 Receptor Antagonist Product Portfolio Table 143. AbbVie Biotechnology Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. IL-23 Receptor Antagonist Distributors List Table 147. IL-23 Receptor Antagonist Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. IL-23 Receptor Antagonist Product Image Figure 2. Global IL-23 Receptor Antagonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-23 Receptor Antagonist Market Size (2021-2032) & (US$ Million) Figure 4. Global IL-23 Receptor Antagonist Sales (2021-2032) & (K Units) Figure 5. Global IL-23 Receptor Antagonist Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 IL-23 Receptor Antagonist Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Briakinumab Image Figure 9. Guselkumab Image Figure 10. Mirikizumab Image Figure 11. Risankizumab Image Figure 12. Tildrakizumab Image Figure 13. Ustekinumab Image Figure 14. Other Image Figure 15. Global IL-23 Receptor Antagonist Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global IL-23 Receptor Antagonist Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global IL-23 Receptor Antagonist Sales Market Share by Type (2021-2032) Figure 18. Global IL-23 Receptor Antagonist Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global IL-23 Receptor Antagonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global IL-23 Receptor Antagonist Revenue Market Share by Type (2021-2032) Figure 21. Plaque Psoriasis Image Figure 22. Crohn's Disease Image Figure 23. Psoriatic Arthritis Image Figure 24. Other Image Figure 25. Global IL-23 Receptor Antagonist Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global IL-23 Receptor Antagonist Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global IL-23 Receptor Antagonist Sales Market Share by Application (2021-2032) Figure 28. Global IL-23 Receptor Antagonist Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 29. Global IL-23 Receptor Antagonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global IL-23 Receptor Antagonist Revenue Market Share by Application (2021-2032) Figure 31. North America IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 32. North America IL-23 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 33. U.S. IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Canada IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Mexico IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Europe IL-23 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 38. Germany IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 39. France IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 40. U.K. IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Italy IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Netherlands IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Asia Pacific IL-23 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 45. China IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Japan IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Korea IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Southeast Asia IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 49. India IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Australia IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South America, Middle East and Africa IL-23 Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 53. Brazil IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 54. South Africa IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Saudi Arabia IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Turkey IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Argentina IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 58. UAE IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Egypt IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Chile IL-23 Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 61. Global IL-23 Receptor Antagonist Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global IL-23 Receptor Antagonist Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 64. North America IL-23 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 66. Europe IL-23 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific IL-23 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa IL-23 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. IL-23 Receptor Antagonist Value Chain Figure 72. Manufacturing Cost Structure Figure 73. IL-23 Receptor Antagonist Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Briakinumab
  • Guselkumab
  • Mirikizumab
  • Risankizumab
  • Tildrakizumab
  • Ustekinumab
  • Other
Applications
  • Plaque Psoriasis
  • Crohn's Disease
  • Psoriatic Arthritis
  • Other
Companies covered
  • Qyuns Therapeutics
  • China Medical System
  • Huadong Medicine
  • Bio-Thera Solutions
  • Teva
  • Sun Pharma
  • Sandoz
  • Samsung Bioepis
  • Janssen Pharmaceuticals
  • Eli Lilly
  • Celltrion
  • Biocon Biologics
  • Amgen
  • Almirall
  • AbbVie Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global IL-23 Receptor Antagonist Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global IL-23 Receptor Antagonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global IL-23 Receptor Antagonist Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global IL-23 Receptor Antagonist Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global IL-23 Receptor Antagonist Market Dynamics
  1. 2.1 IL-23 Receptor Antagonist Industry Trends
  2. 2.2 IL-23 Receptor Antagonist Industry Drivers
  3. 2.3 IL-23 Receptor Antagonist Industry Opportunities and Challenges
  4. 2.4 IL-23 Receptor Antagonist Industry Restraints
3 IL-23 Receptor Antagonist Market by Manufacturers
  1. 3.1 Global IL-23 Receptor Antagonist Revenue by Manufacturers (2021-2026)
  2. 3.2 Global IL-23 Receptor Antagonist Sales by Manufacturers (2021-2026)
  3. 3.3 Global IL-23 Receptor Antagonist Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global IL-23 Receptor Antagonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global IL-23 Receptor Antagonist Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global IL-23 Receptor Antagonist Manufacturers, Product Type & Application
  7. 3.7 Global IL-23 Receptor Antagonist Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global IL-23 Receptor Antagonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 IL-23 Receptor Antagonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 IL-23 Receptor Antagonist Tier 1, Tier 2, and Tier 3
4 IL-23 Receptor Antagonist Market by Type
  1. 4.1 IL-23 Receptor Antagonist Type Introduction
  2. 4.1.1 Briakinumab
  3. 4.1.2 Guselkumab
  4. 4.1.3 Mirikizumab
  5. 4.1.4 Risankizumab
  6. 4.1.5 Tildrakizumab
  7. 4.1.6 Ustekinumab
  8. 4.1.7 Other
  9. 4.2 Global IL-23 Receptor Antagonist Sales by Type
  10. 4.2.1 Global IL-23 Receptor Antagonist Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global IL-23 Receptor Antagonist Sales by Type (2021-2032)
  12. 4.2.3 Global IL-23 Receptor Antagonist Sales Market Share by Type (2021-2032)
  13. 4.3 Global IL-23 Receptor Antagonist Revenue by Type
  14. 4.3.1 Global IL-23 Receptor Antagonist Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global IL-23 Receptor Antagonist Revenue by Type (2021-2032)
  16. 4.3.3 Global IL-23 Receptor Antagonist Revenue Market Share by Type (2021-2032)
5 IL-23 Receptor Antagonist Market by Application
  1. 5.1 IL-23 Receptor Antagonist Application Introduction
  2. 5.1.1 Plaque Psoriasis
  3. 5.1.2 Crohn's Disease
  4. 5.1.3 Psoriatic Arthritis
  5. 5.1.4 Other
  6. 5.2 Global IL-23 Receptor Antagonist Sales by Application
  7. 5.2.1 Global IL-23 Receptor Antagonist Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global IL-23 Receptor Antagonist Sales by Application (2021-2032)
  9. 5.2.3 Global IL-23 Receptor Antagonist Sales Market Share by Application (2021-2032)
  10. 5.3 Global IL-23 Receptor Antagonist Revenue by Application
  11. 5.3.1 Global IL-23 Receptor Antagonist Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global IL-23 Receptor Antagonist Revenue by Application (2021-2032)
  13. 5.3.3 Global IL-23 Receptor Antagonist Revenue Market Share by Application (2021-2032)
6 Global IL-23 Receptor Antagonist Sales by Region
  1. 6.1 Global IL-23 Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IL-23 Receptor Antagonist Sales by Region (2021-2032)
  3. 6.2.1 Global IL-23 Receptor Antagonist Sales by Region (2021-2026)
  4. 6.2.2 Global IL-23 Receptor Antagonist Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America IL-23 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America IL-23 Receptor Antagonist Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe IL-23 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe IL-23 Receptor Antagonist Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific IL-23 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific IL-23 Receptor Antagonist Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa IL-23 Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa IL-23 Receptor Antagonist Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global IL-23 Receptor Antagonist Revenue by Region
  1. 7.1 Global IL-23 Receptor Antagonist Revenue by Region
  2. 7.1.1 Global IL-23 Receptor Antagonist Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global IL-23 Receptor Antagonist Revenue by Region (2021-2026)
  4. 7.1.3 Global IL-23 Receptor Antagonist Revenue by Region (2027-2032)
  5. 7.1.4 Global IL-23 Receptor Antagonist Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America IL-23 Receptor Antagonist Revenue (2021-2032)
  8. 7.2.2 North America IL-23 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe IL-23 Receptor Antagonist Revenue (2021-2032)
  11. 7.3.2 Europe IL-23 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific IL-23 Receptor Antagonist Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific IL-23 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa IL-23 Receptor Antagonist Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa IL-23 Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Qyuns Therapeutics
  2. 8.1.1 Qyuns Therapeutics Company Information
  3. 8.1.2 Qyuns Therapeutics Business Overview
  4. 8.1.3 Qyuns Therapeutics IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Qyuns Therapeutics IL-23 Receptor Antagonist Product Portfolio
  6. 8.1.5 Qyuns Therapeutics Recent Developments
  7. 8.2 China Medical System
  8. 8.2.1 China Medical System Company Information
  9. 8.2.2 China Medical System Business Overview
  10. 8.2.3 China Medical System IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 China Medical System IL-23 Receptor Antagonist Product Portfolio
  12. 8.2.5 China Medical System Recent Developments
  13. 8.3 Huadong Medicine
  14. 8.3.1 Huadong Medicine Company Information
  15. 8.3.2 Huadong Medicine Business Overview
  16. 8.3.3 Huadong Medicine IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Huadong Medicine IL-23 Receptor Antagonist Product Portfolio
  18. 8.3.5 Huadong Medicine Recent Developments
  19. 8.4 Bio-Thera Solutions
  20. 8.4.1 Bio-Thera Solutions Company Information
  21. 8.4.2 Bio-Thera Solutions Business Overview
  22. 8.4.3 Bio-Thera Solutions IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bio-Thera Solutions IL-23 Receptor Antagonist Product Portfolio
  24. 8.4.5 Bio-Thera Solutions Recent Developments
  25. 8.5 Teva
  26. 8.5.1 Teva Company Information
  27. 8.5.2 Teva Business Overview
  28. 8.5.3 Teva IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Teva IL-23 Receptor Antagonist Product Portfolio
  30. 8.5.5 Teva Recent Developments
  31. 8.6 Sun Pharma
  32. 8.6.1 Sun Pharma Company Information
  33. 8.6.2 Sun Pharma Business Overview
  34. 8.6.3 Sun Pharma IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sun Pharma IL-23 Receptor Antagonist Product Portfolio
  36. 8.6.5 Sun Pharma Recent Developments
  37. 8.7 Sandoz
  38. 8.7.1 Sandoz Company Information
  39. 8.7.2 Sandoz Business Overview
  40. 8.7.3 Sandoz IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sandoz IL-23 Receptor Antagonist Product Portfolio
  42. 8.7.5 Sandoz Recent Developments
  43. 8.8 Samsung Bioepis
  44. 8.8.1 Samsung Bioepis Company Information
  45. 8.8.2 Samsung Bioepis Business Overview
  46. 8.8.3 Samsung Bioepis IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Samsung Bioepis IL-23 Receptor Antagonist Product Portfolio
  48. 8.8.5 Samsung Bioepis Recent Developments
  49. 8.9 Janssen Pharmaceuticals
  50. 8.9.1 Janssen Pharmaceuticals Company Information
  51. 8.9.2 Janssen Pharmaceuticals Business Overview
  52. 8.9.3 Janssen Pharmaceuticals IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Janssen Pharmaceuticals IL-23 Receptor Antagonist Product Portfolio
  54. 8.9.5 Janssen Pharmaceuticals Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly IL-23 Receptor Antagonist Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 Celltrion
  62. 8.11.1 Celltrion Company Information
  63. 8.11.2 Celltrion Business Overview
  64. 8.11.3 Celltrion IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Celltrion IL-23 Receptor Antagonist Product Portfolio
  66. 8.11.5 Celltrion Recent Developments
  67. 8.12 Biocon Biologics
  68. 8.12.1 Biocon Biologics Company Information
  69. 8.12.2 Biocon Biologics Business Overview
  70. 8.12.3 Biocon Biologics IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Biocon Biologics IL-23 Receptor Antagonist Product Portfolio
  72. 8.12.5 Biocon Biologics Recent Developments
  73. 8.13 Amgen
  74. 8.13.1 Amgen Company Information
  75. 8.13.2 Amgen Business Overview
  76. 8.13.3 Amgen IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Amgen IL-23 Receptor Antagonist Product Portfolio
  78. 8.13.5 Amgen Recent Developments
  79. 8.14 Almirall
  80. 8.14.1 Almirall Company Information
  81. 8.14.2 Almirall Business Overview
  82. 8.14.3 Almirall IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Almirall IL-23 Receptor Antagonist Product Portfolio
  84. 8.14.5 Almirall Recent Developments
  85. 8.15 AbbVie Biotechnology
  86. 8.15.1 AbbVie Biotechnology Company Information
  87. 8.15.2 AbbVie Biotechnology Business Overview
  88. 8.15.3 AbbVie Biotechnology IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AbbVie Biotechnology IL-23 Receptor Antagonist Product Portfolio
  90. 8.15.5 AbbVie Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IL-23 Receptor Antagonist Value Chain Analysis
  2. 9.1.1 IL-23 Receptor Antagonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IL-23 Receptor Antagonist Production Mode & Process
  6. 9.2 IL-23 Receptor Antagonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IL-23 Receptor Antagonist Distributors
  9. 9.2.3 IL-23 Receptor Antagonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst